Report generated from BNF with QVH Formulary provided by FormularyComplete ( Accessed Formulary Status.
|
|
- Vanessa Copeland
- 5 years ago
- Views:
Transcription
1 Report generated from BNF with QVH Formulary provided by FormularyComplete ( Accessed Title Formulary Status Section TA Number TA Link Annotation A2A Spacer Able Spacer Accolate and phosphodiesterase type-4 inhibitors->3.3.2 Leukotriene receptor antagonists->zafirlukast ACLIDINIUM BROMIDE bronchodilators ACRIVASTINE Acrivastine Alimemazine ALIMEMAZINE TARTRATE ->ACRIVASTINE ->ALIMEMAZINE TARTRATE Alvesco 3.2 Corticosteroids->CICLESONIDE Angioedema emergencies Anoro Ellipta 3.1 Bronchodilators->3.1.4 Compound bronchodilator preparations Asmanex 3.2 Corticosteroids->MOMETASONE FUROATE Atimos Modulite Bambec BAMBUTEROL ->FORMOTEROL FUMARATE ->BAMBUTEROL
2 BEE AND WASP ALLERGEN EXTRACTS Allergen immunotherapy TA246 Not relevant to QVH. Benzoin Tincture, Compound, BP 3.8 Aromatic inhalations BERACTANT 3.5 Respiratory stimulants and pulmonary surfactants->3.5.2 Pulmonary surfactants Berinert emergencies->angioedema->c1-esterase INHIBITOR BILASTINE Bricanyl ->TERBUTALINE SULFATE->Oral and parenteral Bronchitol 3.7 Mucolytics->Mannitol->MANNITOL Not relevant to QVH. Budelin Novolizer 3.2 Corticosteroids->BUDESONIDE BUDESONIDE 3.2 Corticosteroids Budesonide 3.2 Corticosteroids->BUDESONIDE C1-ESTERASE INHIBITOR emergencies->angioedema CICLESONIDE 3.2 Corticosteroids Cinryze CLEMASTINE Codeine Linctus, BP emergencies->angioedema->c1-esterase INHIBITOR 3.9 Cough preparations->3.9.1 Cough suppressants->codeine PHOSPHATE CODEINE PHOSPHATE 3.9 Cough preparations->3.9.1 Cough suppressants Compound preparations ->FORMOTEROL FUMARATE Compound preparations 3.2 Corticosteroids->BUDESONIDE CONESTAT ALFA emergencies->angioedema
3 Curosurf CYPROHEPTADINE 3.5 Respiratory stimulants and pulmonary surfactants->3.5.2 Pulmonary surfactants->poractant ALFA Dornase alfa 3.7 Mucolytics DORNASE ALFA 3.7 Mucolytics->Dornase alfa Eklira Genuair EPHEDRINE Ephedrine Hydrochloride bronchodilators->aclidinium BROMIDE 3.1 Bronchodilators->3.1.1 Adrenoceptor agonists-> Other adrenoceptor agonists 3.1 Bronchodilators->3.1.1 Adrenoceptor agonists-> Other adrenoceptor agonists->ephedrine ERDOSTEINE 3.7 Mucolytics Erdotin 3.7 Mucolytics->ERDOSTEINE Esbriet 3.11 Antifibrotics->PIRFENIDONE Not relevant to QVH. Firazyr emergencies->angioedema->icatibant Flutiform 3.2 Corticosteroids->FLUTICASONE->Compound preparations Foradil Formoterol FORMOTEROL FUMARATE Fostair ->FORMOTEROL FUMARATE ->FORMOTEROL FUMARATE 3.2 Corticosteroids->BECLOMETASONE DIPROPIONATE->Compound preparations Galenphol 3.9 Cough preparations->3.9.1 Cough suppressants->pholcodine GLYCOPYRRONIUM bronchodilators GRASS AND TREE POLLEN EXTRACTS Grass pollen extract Allergen immunotherapy Allergen immunotherapy->grass AND TREE POLLEN EXTRACTS
4 Grazax Hypertonic sodium chloride ICATIBANT Ilaxten Incruse Ellipta INDACATEROL Intal CFC-Free Inhaler Ipratropium bromide with salbutamol Allergen immunotherapy->grass AND TREE POLLEN EXTRACTS->Grass pollen extract 3.7 Mucolytics emergencies->angioedema ->BILASTINE bronchodilators->umeclidinium and phosphodiesterase type-4 inhibitors->3.3.1 Cromoglicate and related therapy->sodium CROMOGLICATE 3.1 Bronchodilators->3.1.4 Compound bronchodilator preparations Ivacaftor 3.7 Mucolytics IVACAFTOR 3.7 Mucolytics->Ivacaftor Kalydeco 3.7 Mucolytics->Ivacaftor->IVACAFTOR KETOTIFEN LEVOCETIRIZINE Levocetirizine Hydrochloride ->LEVOCETIRIZINE Mannitol 3.7 Mucolytics Not relevant to QVH MANNITOL 3.7 Mucolytics->Mannitol TA266 Not relevant to QVH. Menthol and Eucalyptus Inhalation, BP Aromatic inhalations
5 MIZOLASTINE Mizollen ->MIZOLASTINE Modified release 3.1 Bronchodilators->3.1.3 Theophylline->THEOPHYLLINE MOMETASONE FUROATE 3.2 Corticosteroids MucoClear 3% 3.7 Mucolytics->Hypertonic sodium chloride MucoClear 6% 3.7 Mucolytics->Hypertonic sodium chloride Nebusal 7% 3.7 Mucolytics->Hypertonic sodium chloride NEDOCROMIL SODIUM and phosphodiesterase type-4 inhibitors->3.3.1 Cromoglicate and related therapy Nuelin SA 3.1 Bronchodilators->3.1.3 Theophylline->THEOPHYLLINE->Modified release OLODATEROL Omalizumab Allergen immunotherapy Not relevant to QVH. OMALIZUMAB Allergen immunotherapy->omalizumab TA278 Not relevant to QVH. OMALIZUMAB Allergen immunotherapy->omalizumab TA339 Not relevant to QVH. Onbrez Breezhaler ->INDACATEROL OptiChamber OptiChamber Diamond Oxis ->FORMOTEROL FUMARATE Periactin ->CYPROHEPTADINE
6 Pharmalgen Allergen immunotherapy->bee AND WASP ALLERGEN EXTRACTS Not relevant to QVH. Phenergan ->PROMETHAZINE PHOLCODINE 3.9 Cough preparations->3.9.1 Cough suppressants Pholcodine Linctus, BP 3.9 Cough preparations->3.9.1 Cough suppressants->pholcodine Pholcodine Linctus, Strong, BP 3.9 Cough preparations->3.9.1 Cough suppressants->pholcodine PIRFENIDONE 3.11 Antifibrotics TA282 Not relevant to QVH. Pocket Chamber Pollinex PORACTANT ALFA Promethazine PROMETHAZINE Allergen immunotherapy->grass AND TREE POLLEN EXTRACTS 3.5 Respiratory stimulants and pulmonary surfactants->3.5.2 Pulmonary surfactants ->PROMETHAZINE Pulmicort 3.2 Corticosteroids->BUDESONIDE Pulmonary surfactants 3.5 Respiratory stimulants and pulmonary surfactants Pulmozyme 3.7 Mucolytics->Dornase alfa->dornase ALFA Relvar Ellipta 3.2 Corticosteroids->FLUTICASONE->Compound preparations Ruconest Seebri Breezhaler Simple Linctus, Paediatric, BP emergencies->angioedema->conestat ALFA bronchodilators->glycopyrronium 3.9 Cough preparations->3.9.2 Demulcent and expectorant cough preparations
7 Slo-Phyllin SODIUM CROMOGLICATE Space Chamber Plus Striverdi Respimat Survanta 3.1 Bronchodilators->3.1.3 Theophylline->THEOPHYLLINE->Modified release and phosphodiesterase type-4 inhibitors->3.3.1 Cromoglicate and related therapy ->OLODATEROL 3.5 Respiratory stimulants and pulmonary surfactants->3.5.2 Pulmonary surfactants->beractant Symbicort 3.2 Corticosteroids->BUDESONIDE->Compound preparations Tavegil ->CLEMASTINE THEOPHYLLINE 3.1 Bronchodilators->3.1.3 Theophylline Tilade CFC-free Inhaler and phosphodiesterase type-4 inhibitors->3.3.1 Cromoglicate and related therapy->nedocromil SODIUM UMECLIDINIUM bronchodilators Uniphyllin Continus 3.1 Bronchodilators->3.1.3 Theophylline->THEOPHYLLINE->Modified release Vortex Xolair Allergen immunotherapy->omalizumab->omalizumab Only as per NICE guidance. Xyzal ->LEVOCETIRIZINE Zaditen ->KETOTIFEN ZAFIRLUKAST and phosphodiesterase type-4 inhibitors->3.3.2 Leukotriene receptor antagonists
8 ADRENALINE/EPINEPHRINE emergencies->anaphylaxis Topical solution of 1 in 1000 available to reduce blood loss during burns surgery. UNLICENSED use. Adrenaline/Epinephrine 1 in , Dilute emergencies->anaphylaxis->adrenaline/epinephrine->intravenous Adrenaline/Epinephrine 1 in 1000 emergencies->anaphylaxis->adrenaline/epinephrine->intramuscular or subcutaneous AeroChamber Plus Airomir AMINOPHYLLINE 3.1 Bronchodilators->3.1.3 Theophylline Aminophylline 3.1 Bronchodilators->3.1.3 Theophylline->AMINOPHYLLINE Atarax Atrovent Babyhaler BECLOMETASONE DIPROPIONATE Bricanyl ->HYDROXYZINE bronchodilators->ipratropium BROMIDE 3.2 Corticosteroids ->TERBUTALINE SULFATE->Inhalation CARBOCISTEINE 3.7 Mucolytics Carbocisteine 3.7 Mucolytics->CARBOCISTEINE Cetirizine CETIRIZINE ->CETIRIZINE
9 Chlorphenamine CHLORPHENAMINE MALEATE ->CHLORPHENAMINE MALEATE Clenil Modulite 3.2 Corticosteroids->BECLOMETASONE DIPROPIONATE Combivent 3.1 Bronchodilators->3.1.4 Compound bronchodilator preparations DOXAPRAM Emerade EpiPen 3.5 Respiratory stimulants and pulmonary surfactants->3.5.1 Respiratory stimulants emergencies->anaphylaxis->adrenaline/epinephrine->intramuscular injection for self-administration emergencies->anaphylaxis->adrenaline/epinephrine->intramuscular injection for self-administration Flixotide 3.2 Corticosteroids->FLUTICASONE FLUTICASONE 3.2 Corticosteroids Galpseud Haleraid HYDROXYZINE Inhalation Inhalation Intramuscular injection for self-administration Intramuscular or subcutaneous Intravenous 3.10 Systemic nasal decongestants->pseudoephedrine ->SALBUTAMOL ->TERBUTALINE SULFATE emergencies->anaphylaxis->adrenaline/epinephrine emergencies->anaphylaxis->adrenaline/epinephrine emergencies->anaphylaxis->adrenaline/epinephrine
10 IPRATROPIUM BROMIDE bronchodilators Ipratropium Bromide Ipratropium Steri-Neb Jext LORATADINE Loratadine Minijet Adrenaline 1 in Minijet Adrenaline 1 in 1000 bronchodilators->ipratropium BROMIDE bronchodilators->ipratropium BROMIDE emergencies->anaphylaxis->adrenaline/epinephrine->intramuscular injection for self-administration ->LORATADINE emergencies->anaphylaxis->adrenaline/epinephrine->intravenous emergencies->anaphylaxis->adrenaline/epinephrine->intramuscular or subcutaneous Modified release 3.1 Bronchodilators->3.1.3 Theophylline->AMINOPHYLLINE MONTELUKAST Montelukast Oral Oral and parenteral Parenteral Phyllocontin Continus and phosphodiesterase type-4 inhibitors->3.3.2 Leukotriene receptor antagonists and phosphodiesterase type-4 inhibitors->3.3.2 Leukotriene receptor antagonists->montelukast ->SALBUTAMOL ->TERBUTALINE SULFATE ->SALBUTAMOL 3.1 Bronchodilators->3.1.3 Theophylline->AMINOPHYLLINE->Modified release
11 Piriton PSEUDOEPHEDRINE ->CHLORPHENAMINE MALEATE 3.10 Systemic nasal decongestants Qvar 3.2 Corticosteroids->BECLOMETASONE DIPROPIONATE Respontin bronchodilators->ipratropium BROMIDE Salamol Easi-Breathe SALBUTAMOL 1st Line Beta 2 agonist Salbutamol ->SALBUTAMOL->Oral Salbutamol SALMETEROL Salmeterol ->SALMETEROL Seretide 3.2 Corticosteroids->FLUTICASONE->Compound preparations Serevent ->SALMETEROL Simple Linctus, BP 3.9 Cough preparations->3.9.2 Demulcent and expectorant cough preparations Singulair and phosphodiesterase type-4 inhibitors->3.3.2 Leukotriene receptor antagonists->montelukast Sodium Chloride nebulisers->nebuliser diluent Spiriva bronchodilators->tiotropium Standard Range Peak Flow Meter nebulisers->peak flow meters Mini-Wright brand kept.
12 Sudafed TERBUTALINE SULFATE 3.10 Systemic nasal decongestants->pseudoephedrine TIOTROPIUM bronchodilators Ucerax Ventmax SR Ventolin Ventolin Ventolin Volumatic ->HYDROXYZINE ->SALBUTAMOL->Oral ->SALBUTAMOL->Oral ->SALBUTAMOL->Parenteral ACETYLCYSTEINE 3.7 Mucolytics ACETYLCYSTEINE Consultant respiratory physician only for interstitial pulmonary fibrosis. Daxas and phosphodiesterase type-4 inhibitors->3.3.3 Phosphodiesterase type-4 inhibitors->roflumilast Only as per NICE guidance as part of a clinical trial DESLORATADINE Dermatologist use only Desloratadine ->DESLORATADINE Dermatologist use only FEXOFENADINE Dermatologist use only Fexofenadine Hydrochloride ->FEXOFENADINE Dermatologist use only METHADONE 3.9 Cough preparations->3.9.1 Cough suppressants->palliative care Not for this indication
13 Methadone Linctus 3.9 Cough preparations->3.9.1 Cough suppressants->palliative care->methadone Not for this indication. MORPHINE 3.9 Cough preparations->3.9.1 Cough suppressants->palliative care Not for this indication. Neoclarityn ->DESLORATADINE Dermatologist use only ROFLUMILAST and phosphodiesterase type-4 inhibitors->3.3.3 Phosphodiesterase type-4 inhibitors TA244 Only as per NICE guidance as part of a clinical trial. Telfast ->FEXOFENADINE Dermatologist use only Asmabec Clickhaler None 3.2 Corticosteroids->BECLOMETASONE DIPROPIONATE Asmasal Clickhaler None Beclometasone None 3.2 Corticosteroids->BECLOMETASONE DIPROPIONATE Doxapram Hydrochloride None 3.5 Respiratory stimulants and pulmonary surfactants->3.5.1 Respiratory stimulants->doxapram DuoResp Spiromax None 3.2 Corticosteroids->BUDESONIDE->Compound preparations Easyhaler Salbutamol Low Range Peak Flow Meter Pulvinal Salbutamol Salbulin Novolizer None None None None nebulisers->peak flow meters
Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed Formulary Status. TA Number. Section.
Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed 16 02 2017 Title Formulary Status Section TA Number TA Link Annotation ACLIDINIUM BROMIDE bronchodilators ADRENALINE/EPINEPHRINE
More information3. Respiratory System
1 3. Respiratory System Also see Appendix 3A Guidance on Management of Also see Appendix 3B Preferred Inhaler Devices for Adults Also see Appendix 3C Preferred Inhaler Devices for Adolescents (12-18 years)
More informationRespiratory Inhalers. Identification Guide Version 3
Respiratory Inhalers Identification Guide Version 3 This booklet has been prepared by NHSGGC Medicines Information. Endorsed by NHSGGC Respiratory Managed Clinical Network, February 2017. Designed by Medical
More informationRESPIRATORY PRESCRIBING SCHEMES GUIDE 2017/18
impact500 www.ccgprescriber.org RESPIRATORY PRESCRIBING SCHEMES GUIDE 2017/18 TOTAL AVAILABLE NHS SAVINGS IN THIS EDITION 133 MILLION EDITION TWO Analysis was undertaken using May 2017 tariff and February
More informationBNF CHAPTER 3: RESPIRATORY
3.1 BRONCHODILATORS BNF CHAPTER 3: RESPIRATORY 3.1.1.1 SELECTIVE BETA 2 -AGONISTS Short acting Salbutamol 100 micrograms/actuation aerosol inhaler 100 micrograms/actuation breath-actuated (e.g., Easi-Breathe
More informationASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12
North Hampshire CCG Asthma Prescribing Guidelines June 2015 ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12 These guidelines are based on the British Thoracic Society (BTS) and Scottish Intercollegiate
More information500 micrograms/dose Turbohaler dry powder device 500 micrograms/ml injection. 12 micrograms/dose Turbohaler dry powder device
3.1 BRONCHODILATORS 3.1.1.1 SELECTIVE BETA 2 -AGONISTS Short acting Salbutamol Terbutaline 100 micrograms/actuation aerosol inhaler 100 micrograms/actuation breath-actuated e.g. Easi-Breathe 200 micrograms/dose
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationChapter 3: Respiratory System (7 th Edition)
Chapter 3: Respiratory System (7 th Edition) The Sheffield respiratory guidelines (April 2015) have been removed from the intranet. This is because the COPD section has been superseded by the COPD treatment
More information3 - Respiratory. Idiopathic pulmonary fibrosis (IPF), in combination with prednisolone +/- azathioprine
Recommendations from the Lothian Formulary Committee (FC) following Scottish Medicines Consortium (SMC) advice, NICE MTA advice, (FAF3) unlicensed and off-label medicines and (FAF2) medicines not considered
More information3 - Respiratory. Idiopathic pulmonary fibrosis (IPF), in combination with prednisolone +/- azathioprine
Recommendations from the Lothian Formulary Committee (FC) following Scottish Medicines Consortium (SMC) advice, NICE MTA advice, (FAF3) unlicensed and off-label medicines and (FAF2) medicines not considered
More informationCOPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes
COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program
More informationThese lung function tests involve you being seated and breathing into specialist equipment (like that shown below), via a filter and a mouthpiece.
Lung Function Tests This leaflet only gives you general information about the lung function (breathing) tests. However, it does not replace the need for the personal advice from the health care professional.
More informationRESPIRATORY INHALERS
RESPIRATORY INHALERS The correct administration of inhaled therapy is essential for successful, cost-effective and safe therapy. Everyone, including the patient needs to understand the importance of ensuring
More informationPlease also see section on Drugs used in substance dependence for patients with established chemical dependence
Respiratory System Algorithm for the selection of the most appropriate inhaler device for patients with chronic stable asthma Information on Inhaler devices Devices β 2 agonist bronchodilators Antimuscarinic
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationHospital Pharmaceuticals Review PTAC, Hospital Pharmaceuticals Subcommittee & Respiratory Subcommittee minutes for web publishing
Hospital Pharmaceuticals Review PTAC, Hospital Pharmaceuticals Subcommittee & Respiratory Subcommittee minutes for web publishing Respiratory System and Allergies therapeutic group PTAC and Subcommittee
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationRespiratory Health. Asthma and COPD
Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory
More informationGMMMG COPD Formulary Inhaler Options October 2017
BNF 3.1.1 Adrenocepter agonists (SABA) Salbutamol Salbutamol Terbutaline Brand name Airsalb Ventolin Evohaler Bricanyl Turbohaler Device MDI MDI Dry powder Strengths 100 microgram 100 microgram 500 microgram
More informationINHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop
INHALERS for COPD Dr Christopher Worsnop Department of Respiratory Medicine Austin Hospital INTRODUCTION Most drugs for COPD are given via inhalers. This reduces the dose that needs to be given and delivers
More informationCo. Durham & Darlington Respiratory Network COPD Treatment Guide
Co. Durham & Darlington Respiratory Network COPD Treatment Guide Age > 35, Productive cough, Breathless, Smoking Hx Spirometry (post-bronchodilator) COPD Advice Intensive smoking cessation support Vaccination
More informationDose. Route. Units. Given. Dose. Route. Units. Given
Chapter 4 Respiratory Andrew Stanton SALBUTAMOL (in acute asthma) 5 in acute asthma Nebulised (driven by oxygen not air) 4 6 hourly In acute severe asthma not responding to initial treatment or in life-threatening
More informationCOPD Prescribing Guidelines
Cannock Chase Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group East Staffordshire Clinical Commissioning
More information12:00 Autonomic Drugs 12:00. Autonomic Drugs
Autonomic Drugs Autonomic Drugs 12:04 PARASYMPATHOMIMETIC (CHOLINERGIC) AGENTS PILOCARPINE HCL 5 MG ORAL TABLET 00002216345 SALAGEN 1.4298 PYRIDOSTIGMINE BROMIDE 60 MG ORAL TABLET 00000869961 MESTINON
More informationTHEOPHYLLINE WITH INHALED CORTICOSTEROIDS (TWICS) TRIAL SELF MANAGMENT / ACTION PLANS GENUAIR INHALERS: POTENTIAL SAFETY ISSUE
I S S U E 4 M A R C H / A R P I L 2 0 1 6 Endorsed December 2014 I N S I D E T H I S I S S U E : Theophylline with Inhaled Corticosteroids (TWICS) Trial Genuair Inhaler: Potential Safety Issue 1 Self Management
More informationAsthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options
MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More informationMedicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD) Approved by Prof. Michael Barry, Clinical Lead, MMP. Date approved Version 1 July 2014 Date updated Version
More informationBREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)
Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) BREEZHALER Please date initial after you have directly observed
More informationBREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)
Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) BREEZHALER Please date initial after you have directly observed
More informationBREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)
Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) BREEZHALER Please date initial after you have directly observed
More informationSUPPLEMENTARY MATERIAL. Supplementary methods. Optimum Patient Care questionnaires
1 SUPPLEMENTARY MATERIAL Supplementary methods Optimum Patient Care questionnaires Over 600 primary care practices in the United Kingdom contribute data to the Optimum Patient Care Research Database (OPCRD).
More informationRespiratory system. Contents: 1. Asthma acute exacerbations
Respiratory system Medicines Formulary Contents: 1. Asthma acute exacerbations 1 2. Asthma chronic 4 3. Chronic obstructive pulmonary disease acute exacerbations 6 4. Chronic obstructive pulmonary disease
More informationMethacholine Challenge Test
PATIENT & CAREGIVER EDUCATION Methacholine Challenge Test This information will help you prepare for your methacholine challeng e test at Memorial Sloan Kettering (MSK). A methacholine (meth-a-kole-leen)
More informationChronic Obstructive Pulmonary Disease
Page 1 of 12 Chronic Obstructive Pulmonary Disease Chronic obstructive pulmonary disease (COPD) is an umbrella term for people with chronic bronchitis, emphysema, or both. With COPD the airflow to the
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationSummary of Lothian Joint Formulary Amendments
Summary of Lothian Joint Formulary Amendments The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons for some of the changes. The
More informationStepping down asthma treatment guidelines
Stepping down asthma treatment guidelines The potential for inhaled corticosteroids (ICS) to cause dose-related side-effects has led to asthma management guidelines recommending a dose reduction once asthma
More information3 RESPIRATORY SYSTEM
3 RESPIRATORY SYSTEM 3.01 ANTIASTHMATICS 3.01a BETA 2 AGONIST ASTHMA, CHRONIC BRONCHITIS & EMPHYSEMA Salbutamol Inhaler 100ug/dose [Albuterol] (Ventolin) Salbutamol Sulphate Respirator Solution 0.5% (5mg/ml),
More informationCHARM ASTHMA TREATMENT GUIDELINE
NHS City and Hackney Prescribing Guidelines Adults ( 12 years of age) CHARM ASTHMA TREATMENT GUIDELINE Written by: Hetal Dhruve (Specialist Respiratory Pharmacist, City and Hackney CCG) Checked by: Prof
More informationCHARM Guidelines for the diagnosis and
\ CHARM Guidelines for the diagnosis and management of COPD City and Hackney CCG Homerton University Hospital NHS Foundation Trust Written by: Miss Hetal Dhruve, Specialist Pharmacist Respiratory Medicine,
More informationStepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs
Step Down guidance Stepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs Important Complete asthma control needs to be achieved for at least 12 weeks before attempting to step patients
More informationPosition within the Organisation
ASTHMA TREATMENT GUIDELINES Document Description Document Type Service Application Guidelines All healthcare professionals(hcps) caring for patients with asthma Version 4.0 Ratification date September
More informationCOPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre
COPD The New Epidemic Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre Conflict Disclosure Information Speaker: Dr. Peter Lin Title of Talk: COPD The New Epidemic Financial
More informationInhalers containing CFCs. CFC-free inhalers
Propellants used in medical metered dose inhalers and aerosol-based breath activated devices in New Zealand August to October 2002 (most recent period for which data is available) (February 2003) Inhalers
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
CINQAIR (reslizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationGreater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma
Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Non-pharmacological options for ALL patients, consider at ALL stages Make sure diagnosis
More informationInhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.
Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. AccuNeb inhalation 0.021% solution: 0.63mg/3mL 3-4 times solution
More informationREVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE
REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE ID NUMBER: 0a) Date of Collection / / 0b) Staff Code Instructions: This form should be completed during the participant s clinic visit. 1) Are you regularly
More informationSelect Inhaled Respiratory Agents
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationHe is still Short of Breath Is there any new puffer? Saidul Ansary
He is still Short of Breath Is there any new puffer? Saidul Ansary Mr S C 66 yr. old retired Engineer for pre op elective assessment I am fine but Anaesthetist said I need to see you. I am little bit SOB,
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationLungs SLO Practice (online) Page 1 of 5
Lungs SLO Practice (online) Page 1 of 5 1. A 15 year- old teen has asthma. A nebulizer treatment has been ordered. The type of medication most likely to be used in this treatment for asthma management
More informationTRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Xolair (omalizumab) Policy Number: MP-051-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective
More informationDiagnosis and management of Asthma in Adults. (Version 1.1)
Pan-Birmingham Respiratory Clinical Network Diagnosis and management of Asthma in Adults (Version 1.1) Revision History Guideline Author: Guideline Sponsor: Date of Approval: 23/03/2017 Approved by: Date
More informationCOPD Inhaled Therapy Prescribing Guidance
COPD Inhaled Therapy Prescribing Guidance For Basingstoke, Southampton and Winchester District Prescribing Committee This guidance applies to patients with a COPD DIAGNOSIS CONFIRMED BY POSTBRONCHODILATOR
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung
More informationNHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
More informationFoundations of Pharmacology
Pharmacologic Management of Asthma Objectives: 1. Review the physiological basis for asthma therapy 2. Discuss the differences between SABA and LABA 3. Discuss the role of inhaled and oral systemic corticosteroids
More informationCOPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy
Update: Focus on Intensifying LABA, LAMA and ICS Therapy B.C. Provincial Academic Detailing Service February 2017 Background In Canada, approximately 20 inhaled medications are approved to treat Chronic
More informationSpirometry is a test that measures the size of your lungs and it also measures airflow in your lungs.
PATIENT INFORMATION This leaflet gives you general information about the lung function (breathing) tests. However, it does not replace the need for personal advice from the health care professional. Please
More informationreslizumab (Cinqair )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationCOPD Inhaled Therapy Prescribing Guidance
COPD Inhaled Therapy Prescribing Guidance For Basingstoke, Southampton and Winchester District Prescribing Committee This guidance applies to patients with a COPD DIAGNOSIS CONFIRMED BY POSTBRONCHODILATOR
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationAddress Comorbidities
Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure
More informationANTINEOPLASTIC DRUGS CHAPTER 21. Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component
ANTINEOPLASTIC DRUGS CHAPTER 21 Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component Tx of malignancies Antineoplastic drugs: methotrexate
More informationAdult Summary flowchart for Asthma Switch and Step Down to preferred inhaler choices
HVCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 1 of 6 Adult Summary flowchart for Asthma Switch and Step Down to preferred
More informationCOPD RESOURCE PACK Section 5. Drug Treatment & Inhalers in Stable COPD
COPD RESOURCE PACK Section 5 Drug Treatment & Inhalers in Stable COPD In this section: 1. Links to Fife Formulary 2. Pharmacological Management of Stable COPD 3. How to use a Metered Dose Inhaler 4. How
More informationBetter Living with Obstructive Pulmonary Disease A Patient Guide
Better Living with Obstructive Pulmonary Disease A Patient Guide Second Edition November 2012 Queensland Health a Better Living with Chronic Obstructive Pulmonary Disease A Patient Guide is a joint project
More informationChronic Obstructive Pulmonary Disease (COPD) Primary Care Guideline
Chronic Obstructive Pulmonary Disease (COPD) Primary Care Guideline For use across all Norfolk & Waveney CCGs Based on GOLD 2017 1, NICE CG101 COPD 2. Norfolk & Waveney Group In the UK in 2012, 29,776
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects
More informationAdult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred inhaler choices
ENHCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 1 of 6 Adult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred
More informationFASENRA (benralizumab)
FASENRA (benralizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationAsthma. Definition. Symptoms
Asthma Definition Asthma is a condition in which your airways narrow and swell and produce extra mucus. This can make breathing difficult and trigger coughing, wheezing and shortness of breath. For some
More informationDrug Effectiveness Review Project Summary Report
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationWhy Asthma Still Kills The National Review of Asthma Deaths (NRAD)
APPROVED FINAL VERSION NHS Protect Why Asthma Still Kills The National Review of Asthma Deaths (NRAD) Summary of Recommendations for GP Practices and Community Pharmacies Author: Anne Henry Contact: anne.henry@nhs.net
More informationSABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA
COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE Bulletin 218: September 2015 Review Date: September 2018 LAMA / LABA combination inhalers in COPD- Place in therapy review and choice of therapy JPC Recommendations:
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE September 2015 Review Date: September 2018 Bulletin 219: Choice of Long Acting Muscarinic Agent (LAMA) inhaler for COPD JPC Recommendation: The availability
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationFerris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS
Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the
More information31 - Respiratory System
31 - Respiratory System Asthma 1. Asthma has two components. Name the two components. 2. What are the common triggers of asthma? (LP p319) (e.g., pets) Upper respiratory infections ( ) 3. Describe a normal
More informationRespiratory Inhaler Check-up Service
Respiratory Inhaler Check-up Service Dr Toby Capstick Lead Respiratory Pharmacist Leeds Teaching Hospitals NHS Trust toby.capstick@nhs.net 8 th May 2018 What is the Challenge? The Burden of Disease in
More informationAsthma Treatment Guideline for Adults (aged 17 and over)
Asthma Treatment Guideline for Adults (aged 17 and over) Sharon Andrew MLCSU January 2019 (Review date 0 January 2022) VERSION CONTROL. Please access via the LMMG website to ensure that the correct version
More informationASTHMA TREATMENT GUIDE (ADULTS)
ASTHMA TREATMENT GUIDE (ADULTS) The BTS/SIGN guideline provides a wide range of information and guidance on the treatment of patients with asthma. https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016/
More informationWhat is the Challenge?
Respiratory Inhaler Check-up Service What is the Challenge? Dr Toby Capstick Lead Respiratory Pharmacist Leeds Teaching Hospitals NHS Trust toby.capstick@nhs.net 25 th September 2018 The Burden of Disease
More informationEnd Stage COPD Guidance Document
End Stage COPD Guidance Document Suggested Guidelines for the Determination of Hospice Eligibility A patient with severe chronic pulmonary disease that meets the following criteria may be eligible for
More informationCommon Drug Review Pharmacoeconomic Review Report
Common Drug Review Pharmacoeconomic Review Report January 2018 Drug umeclidinium bromide (Incruse Ellipta) Indication Listing request Dosage form(s) Manufacturer Indicated for long-term, once daily maintenance
More informationcontrol in the lowest dose providing adequate Maintain high dose ICS Use daily steroid tablet dose Consider trials of: Increasing ICS up to
Summary of management in adults sthma - suspected dult asthma - diagnosed Diagnosis and ssessment Evaluation: assess symptoms, measure lung function, check inhaler technique and adherence adjust dose update
More informationChronic Obstructive Pulmonary Disease (COPD) Management
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Chronic Obstructive Pulmonary Disease (COPD) Management Diagnosis of COPD should be considered in patients over the age of 35 who have a risk factor (generally
More informationSTRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationGMMMG Asthma Formulary Inhaler Options August 2017
Regular Preventer Beclometasone Beclometasone Beclometasone Brand name Qvar Easi-Breathe Clenil Modulite Easyhaler Device MDI MDI DPI Strengths 50 microgram 100 microgram 200 microgram Adult asthma 2 inhalations
More information